Ascletis Pharma’s investigational Ganovo and Ritonavir combo-therapy shows promise in COVID-19 Clinical Trial.
Chinese biotech Ascletis Pharma Inc. (HKEX code: 1672) announces progress of the small sample clinical trial of Ganovo® and Ritonavir combination therapy on Novel Coronavirus Pneumonia.
One of the treatment groups in this study is the group receiving oral Ganovo® and Ritonavir combination therapy, in which 10 Novel Coronavirus Pneumonia patients were planned to be enrolled, and 11 patients actually enrolled.
All of the 11 patients receiving a combination of oral Ganovo® and Ritonavir have been discharged as they are satisfied with the discharge standards under the “Diagnosis and Treatment Program for Novel Coronavirus Infection (Trial Version 6)” issued by the National Health Commission of the People’s Republic of China.
In February, the combination clinical trial of oral Ganovo® and Ritonavir medication, spearheaded by the director of the Ninth Hospital of Nanchang, Dr. Hongyi CHEN, obtained approval from the ethics committee. Dr. Jinzi J. Wu, Founder, Chairman and Chief Executive Officer of Ascletis stated:
“We are pleased that our anti-viral drugs are contributing to fighting the epidemic of novel coronavirus and curing patients.”